SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, amended upper-limb data and recent commercial-launch job postings. Many expect approval and anticipate short covering, while others stress that hiring and FDA rare-disease messaging are not proof of a favorable decision and point to the prior setbacks and remaining efficacy questions.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios reported FDA approval of a competing RRP treatment has fueled debate over the threat to Precigens PAPZIMEOS and whether the selloff is an overreaction; traders disagree on the therapies relative advantages and Precigens commercial head start. Attention is also turning to upcoming PRGN-2009 clinical data and a Q3 business update.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Shares are climbing to a fresh 52-week high as traders position ahead of the expected Q3 report, with BRIUMVI sales growth supporting optimism. Some also speculate about a potential buyout or short squeeze, but the takeover chatter is unconfirmed, and others attribute the move to earnings expectations and momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas announced addition to the S&P 500, replacing Kenvue, is drawing attention, with traders weighing index-related buying against a possible sell-the-news reaction. Some posts also raise unverified claims about a DHS-related breach, but they do not appear to be the main catalyst.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares post-TDAPA reimbursement contribution for DefenCath could decline through 2027 is driving the sharp selloff and debate over future revenue. Some traders view the comments as a serious pricing risk, while others argue DaVitas estimates are preliminary and point to CMSs more favorable payment assumptions; several describe the decline as an overreaction.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers upcoming quarterly earnings report is the main focus, with traders watching whether results and guidance can support the recent rally. Sentiment is split between hopes for an earnings beat and renewed strength in big pharma, and concerns about the companys growth outlook and patent expirations.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Lines stronger-than-expected third-quarter results and raised full-year outlook sparked a sharp rally, with traders debating whether heavy short interest could amplify the move. The reaction is mixed: some see evidence of a turnaround, while others point to profit-taking, fuel-cost pressures and lingering concerns about bookings and yields.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reaching its prespecified 80th death event triggered final analysis and heightened anticipation of topline results for its GPS treatment in AML. Traders are sharply divided: bulls see potential for strong survival data, while skeptics question the trials control-arm assumptions and point to the share-price weakness as a reason for caution.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq selloff has put QQQ in correction territory, with traders linking the pressure to weakness across technology and AI-related stocks, worries about returns on heavy AI spending, and rising-rate concerns. The community is split between bears expecting further losses and dip-buyers anticipating a relief bounce or short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600PR NewswireNEW YORK, Oct. 30, 2026 NEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500...

LiveRamp (RAMP) Tops Q1 Earnings and Revenue Estimates

LiveRamp (RAMP) delivered earnings and revenue surprises of +18.18% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LiveRamp Adds Meta to Cross-Media Intelligence

LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced it has expanded its Cross-Media Intelligence solution to enable cross-media measurement across Meta and other media channels, such as CTV, programmatic, social, and audio, enabling brand marketers to measure campaigns across...

New MMA and LiveRamp Report Finds Even Small Data Gaps and Identity Errors Can Distort Marketing Measurement

LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced new research developed in collaboration with the Marketing + Media Alliance (MMA), examining the impact of incomplete and inconsistently linked marketing measurement. Critically, The Missing Piece: Improving Confidence in...

Are RAMP, AVB, EQR, NEE Obtaining Fair Deals for their Shareholders?

Are RAMP, AVB, EQR, NEE Obtaining Fair Deals for their Shareholders? Are RAMP, AVB, EQR, NEE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 14, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

LiveRamp Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LiveRamp Holdings, Inc. - RAMP

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of LiveRamp Holdings, Inc. (NYSE: RAMP) to Publicis Groupe. Under the terms of the proposed transaction, shareholders of LiveRamp will receive $38.50...

ZETA Rides AI and Agency Shifts as Marketing Platforms Evolve Fast

ZETA reflects fast-changing marketing tech trends as AI adoption, vendor consolidation and agency expansion collide with margin and cash-timing friction.

Is ZETA Stock a Buy as Growth Beats Meet Estimate Pressure in 2026?

ZETA's rapid growth, AI adoption and raised 2026 outlook face a tougher buy case as estimated pressure, margins and limited upside cloud the setup.

ZETA Stock Outlook Hinges on AI Growth and Margin Trade-Offs in 2026

ZETA's AI platform is gaining enterprise traction, but 2026 margin pressure from agency-led social channels keeps the stock outlook less settled.


Are CRBG, TBRG, GBTG, RAMP Obtaining Fair Deals for their Shareholders?

Are CRBG, TBRG, GBTG, RAMP Obtaining Fair Deals for their Shareholders? Are CRBG, TBRG, GBTG, RAMP Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 2, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

LiveRamp Holdings, Inc. is a global technology company, which engages in the provision of a data collaboration platform in consumer privacy, data ethics, and foundational identity. The company was founded in 1969 and is headquartered in San Francisco, CA.

LiveRamp Holdings Inc

Liveramp Stock Soars 23% On Strong Q4 Print, Price Target Hikes On Wall Street: But Retail Turns Bearish 

Equity

Bullish Sentiment

Liveramp Holdings Inc. (RAMP) shares jumped&nbsp;23% on Thursday morning after&nbsp;reporting better-than-expected fourth-quarter (Q4) earnings.The software-as-a-service (SaaS) company’s Q4 revenue climbed 10% year-on-year (YoY) to&nbsp;$189 million, beating the analyst consensus estimate of $185.41 million, as per Finchat data.The adjusted earnings per share (EPS) of $0.30 also&nbsp;surpassed the consensus estimate of $0.28.Following the earnings, Wall Street analysts raised their price targets to reflect optimism.Wells Fargo increased its price target to $31 from $26 while maintaining an&nbsp;‘Equal Weight’ rating on the stock, as per TheFly.&nbsp;Wells also highlighted the company’s solid performance in Q4 2025 and noted that its FY26 revenue guidance&nbsp;was 3% above expectations at the high end.&nbsp;Additionally, the brokerage said remaining performance obligations (RPO) showed stronger momentum, rising 25% YoY in Q4 compared to 6% in the third quarter (Q3). However, this growth was primarily fueled by contract renewals rather than new customer acquisitions.Benchmark has raised its price target to $48 from $45 and continues to rate the stock as a ‘Buy’.&nbsp;The firm praised the company’s&nbsp;latest quarterly performance, calling it “an exceptional quarter” despite ongoing challenges in commerce media and broader economic uncertainty.&nbsp;Although LiveRamp still faces macroeconomic headwinds, the brokerage pointed out that management’s FY26 revenue outlook includes what they described as a “healthy dose of conservatism,” even at the lower end of the forecast.On Stocktwits, retail sentiment around Liveramp changed to ‘bearish’ from ‘bullish’ the previous day.<figure class="image"><img style="aspect-ratio:631/72;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_22_094949_png_8ea9ed60b9.webp" alt="RAMP's Sentiment Meter and Message Volume as of 10:00 a.m. ET on May 22, 2025 | Source: Stocktwits" width="631" height="72"><figcaption>RAMP's Sentiment Meter and Message Volume as of 10:00 a.m. ET on May 22, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RAMP">Liveramp</a> stock has gained over 12% in 2025 and 5% in the last 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/aurora-mobile-global-contracts-surge-past-13-million-usd/ch09JnCRbp0">Aurora Mobile’s Global Contracts Surge Past $13M: Retail’s Exuberant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LiveRamp Holdings logo is seen displayed on a smartphone screen. 

Analysts raised price targets, citing strong guidance and resilient performance despite macroeconomic challenges.

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

RAMP LiveRamp Holdings Inc

Fundamentals

Latest RAMP News